Here’s our fortnightly wrap of all the news driving ASX health stocks.

It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat.

Code Company Price % return since March 3 %YTD return % return since 17/3/20 MktCap
SHG Singular Health 69.5 10.3 $32,515,575
RAC Race Oncology 391 0.0 123.4 1375.5 $555,007,430
AMT Allegra Orthopaedics 30 -17.8 -14.3 130.8 $31,337,761
RSH Respiri 16 10.3 23.1 116.2 $111,962,822
NC6 Nanollose 12.5 25.0 131.5 245.4 $13,702,146
CAJ Capitol Health 32 -5.8 18.2 46.7 $328,783,204
CGS Cogstate 95.5 -5.9 -13.2 176.8 $158,321,648
NSB Neuroscientific 24 2.1 -4.0 65.5 $26,840,277
PYC PYC Therapeutics 15 3.4 1.7 196.3 $459,784,285
ACW Actinogen Medical 3.4 47.8 61.9 116.8 $51,477,315
RNO Rhinomed 12 -11.1 -25.0 20.0 $31,726,142
JHC Japara Healthcare Lt 74.5 -11.3 20.2 61.1 $203,107,969
RHY Rhythm Biosciences 144 -5.6 64.6 2737.4 $302,356,217
BWX BWX 480 11.9 17.0 74.0 $675,447,189
SVA Simavita 1.7 0.0 6.3 -5.6 $23,671,965
ALC Alcidion Group 29 11.5 56.8 114.8 $292,254,745
MX1 Micro-X 34.5 -15.9 -2.8 142.5 $170,089,644
TD1 Tali Digital 4.8 -2.0 2.1 152.6 $43,701,717
RGS Regeneus 11.5 -8.0 -8.0 64.3 $36,034,126
ICR Intelicare Holdings 28 3.7 16.7 $10,640,545
CDY Cellmid 8 -6.6 -21.9 -14.0 $9,795,347
TRU Truscreen 9 -6.3 $32,657,963
EYE Nova EYE Medical 33.5 0.0 -5.6 11.8 $48,134,856
PNV Polynovo 272 11.0 -29.9 80.1 $1,818,817,121
ICS ICSGlobal 204 1.5 -3.3 22.6 $21,468,999
4DX 4Dmedical 154 -11.0 -36.6 $313,076,628
TLX Telix Pharmaceutical 421 5.3 11.4 325.3 $1,166,379,586
EZZ EZZ Life Science 80 -31.0 $8,940,000
ALT Analytica 0.3 0.0 0.0 50.0 $8,799,031
SDI SDI 81 1.9 3.2 8.3 $96,281,079
OVN Oventus Medical 20 -4.8 -14.9 -40.3 $31,652,483
JHL Jayex Healthcare 5 8.7 28.2 284.6 $10,873,603
RAP Resapp Health 7.3 23.7 -14.1 -12.0 $59,620,820
APH AP Hemp 45.5 -1.1 33.8 468.8 $35,819,814
FFC Farmaforce 9.9 0.0 10.0 65.0 $12,937,417
ADR Adherium 2.1 16.7 -25.0 16.7 $14,271,516
AHK Ark Mines 3.4 0.0 0.0 0.0 $1,778,920
EPN Epsilon Healthcare 23 -6.1 -2.1 4.5 $42,852,814
CYP Cynata Therapeutics 66.5 2.3 -2.9 -12.2 $93,129,786
CHM Chimeric Therapeutic 32.5 4.8 $59,932,500
1ST 1St Group 3.4 6.3 0.0 13.3 $15,286,209
ONT 1300 Smiles 742 2.0 12.4 39.9 $168,826,878
LBT LBT Innovations 9.5 -4.0 -22.4 -13.6 $28,333,286
UBI Universal Biosensors 53 24.7 21.8 253.3 $88,767,184
GSS Genetic Signatures 164 0.0 -18.4 64.0 $235,743,331
MDR Medadvisor 33.5 -9.5 -5.6 -19.1 $120,424,851
M7T Mach7 Tech 122.5 -13.4 -2.0 142.3 $274,955,129
HCT Holista CollTech 6.4 -9.9 -11.1 -27.3 $18,173,040
NEU Neuren Pharmaceut. 130.5 -0.4 1.6 8.8 $151,282,703
PBP Probiotec 228 3.6 -4.2 18.6 $178,111,932
PAR Paradigm Bio. 251 2.0 -1.6 75.5 $569,153,461
ARX Aroa Biosurgery 120 -0.8 4.3 $351,849,904
AGH Althea Group 54.5 5.8 25.3 194.6 $141,681,712
1AD Adalta 18.5 8.8 48.0 201.2 $44,131,654
MVF Monash IVF Group 72.5 -1.2 -5.0 21.0 $282,485,259
MEM Memphasys 8.1 -22.9 -19.0 113.2 $54,703,719
SOM SomnoMed 190 7.2 -9.5 10.7 $153,104,733
OSX Osteopore 45 0.0 -13.5 28.6 $35,117,010
S66 Star Combo 29 0.0 -12.1 -38.3 $39,066,616
HXL Hexima 16.5 17.9 -10.8 -45.9 $19,861,447
PGC Paragon Care 23 -14.8 2.2 53.3 $74,334,764
RCE Recce Pharmaceutical 102.5 -1.0 -2.8 259.6 $175,515,625
OPT Opthea 160.5 -0.6 -16.4 -14.6 $567,093,363
OIL Optiscan Imaging 23 2.2 119.0 1433.3 $140,805,021
CYC Cyclopharm 255 0.8 2.0 220.0 $234,370,806
OSL Oncosil Medical 9.2 -12.4 -23.3 2.0 $75,890,270
IMU Imugene 12 20.0 20.0 566.7 $547,353,921
MEB Medibio 0.9 0.0 12.5 85.3 $12,559,078
NOX Noxopharm 68.5 -1.4 39.8 356.3 $191,027,559
PIQ Proteomics Int Lab 131.5 5.2 65.4 526.2 $139,724,314
AT1 Atomo Diagnostics 27 10.2 -11.5 $112,169,843
MVP Medical Developments 550 0.0 -17.7 11.3 $399,794,810
VTI Vision Tech, 1.8 -5.3 -28.0 -35.7 $16,893,335
IVX Invion 0.9 0.0 -10.0 28.6 $49,840,131
VLS Vita Life Sciences.. 119 30.8 19.0 88.8 $59,490,873
OSP Osprey Med 2.1 16.7 -4.5 75.0 $53,881,386
CAN Cann Group 58.5 -5.6 -0.8 -14.0 $165,317,451
VBS Vectus Biosystems 125 0.0 4.2 113.7 $39,569,243
ACR Acrux 15.5 -8.8 -6.1 40.9 $45,189,577
BPH BPH Energy 11.5 -30.3 167.4 1226.0 $79,790,327
MDC Medlab Clinical 29.5 -7.8 22.9 40.5 $82,504,323
DVL Dorsavi 4.1 28.1 0.0 152.3 $12,282,640
DOC Doctor Care Anywhere 101.5 -16.8 -15.4 $181,724,249
OCC Orthocell 52 1.0 15.6 103.9 $98,172,244
PAA Pharmaust 10 2.0 -4.8 42.9 $31,039,532
PXS Pharmaxis 8.7 6.1 -6.5 29.9 $33,367,639
BIT Biotron 6.8 -1.4 -12.8 -29.9 $49,837,223
PAB Patrys 2.4 -7.7 0.0 72.6 $45,300,420
AHC Austco Healthcare 9.5 5.6 -4.0 35.7 $26,713,761
NYR Nyrada 31.5 0.0 31.3 152.0 $24,481,728
KZA Kazia Therapeutics 134.5 1.9 15.9 157.5 $170,220,193
LSH Lifespot Health 12 -4.0 55.8 312.1 $20,216,035
CMP Compumedics 40.5 -3.6 -19.0 1.3 $76,180,068
BXN Bioxyne 1.3 8.3 8.3 30.0 $8,962,036
PSQ Pacific Smiles Grp 260 -3.7 2.0 143.0 $407,769,039
AVE Avecho Biotech 2.2 4.8 -24.1 633.3 $42,064,578
ANP Antisense Therapeut. 18 12.5 38.5 339.0 $106,200,349
GTG Genetic Technologies 0.9 -25.0 20.0 125.0 $81,150,541
NXS Next Science 127 2.4 1.6 -20.1 $145,624,322
ONE Oneview Healthcare 22 182.1 388.9 417.1 $77,568,640
DXB Dimerix 26.5 12.8 12.8 96.3 $50,489,821
IDT IDT Australia 18.5 -2.6 0.0 85.0 $46,846,734
SCU Stemcell United 2.7 -3.6 42.1 170.0 $22,688,658
SUD Suda Pharmaceuticals 4.3 -4.4 7.5 10.3 $16,540,208
ZNO Zoono Group 69.5 0.0 -47.1 -52.9 $115,787,583
BD1 Bard1 Life Sciences 390 33.6 473.5 490.9 $328,098,293
BOT Botanix Pharma 11.5 0.0 -8.0 43.8 $111,911,339
IMC Immuron 21.5 2.4 -6.5 156.0 $48,858,018
IBX Imagion Biosys 16 -5.9 10.3 907.6 $175,562,066
LCT Living Cell Tech. 1.6 -5.9 14.3 23.1 $8,571,615
CDX Cardiex 6.9 -9.2 23.2 283.3 $65,630,068
CP1 Cannpal Animal 17 3.0 0.0 61.9 $15,831,250
CTE Cryosite 25.5 27.5 -35.4 254.2 $11,480,593
MMJ MMJ Group Hlds 11.5 -4.2 -8.0 51.3 $27,594,478
PCK PainChek 7.6 -6.2 -1.3 2.7 $77,749,531
ZLD Zelira Therapeutics 6.8 1.5 -26.1 119.4 $78,561,316
CPH Creso Pharma 19 -7.3 5.6 216.7 $181,169,749
CBL Control Bionics 61 -6.2 -35.1 $30,572,395
ATH Alterity Therap 3.4 0.0 9.7 161.5 $70,856,567
ATX Amplia Therapeutics 26 8.3 8.3 462.2 $27,503,974
EXL Elixinol Global 20 2.6 14.3 -7.3 $66,083,515
IMM Immutep 37 10.4 -10.8 17.5 $240,028,356
AC8 Auscann Grp Hlgs 15 -3.2 -23.1 -9.1 $49,142,340
NTI Neurotech Intl 6.6 -5.7 46.7 1220.0 $37,756,894
VHT Volpara Health Tech 129.5 -0.4 -9.8 12.6 $328,834,996
IPD Impedimed 10.5 -4.5 -16.0 64.9 $131,800,728
PAL Palla Pharma 51 -12.8 -33.8 -22.3 $75,173,989
PTX Prescient 10 9.9 49.3 270.4 $64,055,301
IHL Incannex Healthcare 21 5.0 35.5 467.6 $227,197,072
BNO Bionomics 24 -20.1 79.1 625.2 $232,522,037
RHT Resonance Health 18 -5.3 -25.0 80.0 $80,649,097
GLH Global Health 43 19.4 -8.5 218.5 $18,102,278
MXC Mgc Pharmaceuticals 7.2 -10.0 188.0 323.5 $163,223,298
ADO Anteotech 20.5 7.9 95.2 1181.3 $374,748,269

Oneview Health (ASX:ONE) has been by far the biggest gainer, soaring 182 per cent in the period from March 3 to March 17 after entering into an investor awareness agreement with StocksDigital, the publisher of nextinvestors.com, wise-owl.com and catalysthunter.com.

Oneview says it will pay 6.25 million in shares in lieu of a $375,000 payment to StocksDigital for research and coverage over the next 18 months, and has agreed to sell StocksDigital another $1 million in shares at 6c – what was then an 18.9 per cent discount.

Next Investors recommended Oneview on March 12 as its “Technology Pick of the Year for 2021”, emailing subscribers that this was “the most undervalued company we have seen in ages”.

Oneview shares haven taken off since then, rising 175 per cent from 8c to 22c, taking its market capitalisation from $32 million to $88 million.

The company is working on the upcoming global launch of its cloud-based tablet solution for hospitals to manage patients at their bedside.

Actinogen Medical (ASX:ACW) was the second-biggest gainer, advancing 47.8 per cent to 3.4c. An announcement on Monday that Actinogen had appointed Dr Steven Gourlay as chief executive has seemed to boost sentiment. He’s been consulting for the company since December.

Actinogen is working to develop its lead drug compound, Xanamen, as a therapy for Alzheimer’s disease, Fragile X syndrome, schizophrenia and diabetes. It works by blocking the production of intracellular cortisol, the “stress hormone”.

Bard1 Life Sciences (ASX:BD1) rounds out the top three with a 33.6 per cent gain on a string of positive news including an Australian patent and promising early work on its exosome research to detect pancreatic cancer.

On the flip side, beauty and wellness company EZZ Life Science (ASX:EZZ) has fallen 31 per cent in the two weeks since March 3 – the day it listed.

EZZ shares have traded as high as $1.425 over the period but closed Wednesday at 80c – still up from its 50c IPO price.

Oneview, Actinogen, Bard1 and EZZ share chart